Press release
Castrate Resistant Prostrate Cancer Pipeline Outlook Report 2025: Key 5+ Companies and Breakthrough Therapies Shaping the Future Landscape
Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report
* In August 2025, Pfizer conducted a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naive.
* DelveInsight's Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
* The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
* Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab , and others.
Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer Emerging Drugs
* Niraparib: Janseen
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
* Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
The Castrate Resistant Prostrate Cancer Pipeline analysis report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Castrate Resistant Prostrate Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Castrate Resistant Prostrate Cancer Treatment.
* Castrate Resistant Prostrate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Castrate Resistant Prostrate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Castrate Resistant Prostrate Cancer market.
Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer Companies
Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravitreal
* Subretinal
* Topical.
* Molecule Type
Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Castrate Resistant Prostrate Cancer Pipeline Report
* Coverage- Global
* Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
* Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Castrate Resistant Prostrate Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Castrate Resistant Prostrate Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Castrate Resistant Prostrate Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Niraparib: Janseen
* Mid Stage Products (Phase II)
* ZEN003694: Newsoara Biopharma
* Early Stage Products (Phase I)
* EPI7386: ESSA Pharma
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Castrate Resistant Prostrate Cancer Key Companies
* Castrate Resistant Prostrate Cancer Key Products
* Castrate Resistant Prostrate Cancer- Unmet Needs
* Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
* Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
* Castrate Resistant Prostrate Cancer Analyst Views
* Castrate Resistant Prostrate Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castrate-resistant-prostrate-cancer-pipeline-outlook-report-2025-key-5-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/castrate-resistant-prostrate-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate Resistant Prostrate Cancer Pipeline Outlook Report 2025: Key 5+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4146459 • Views: …
More Releases from ABNewswire
CloudMile Named Strategic Partner to Drive Enterprise AI Adoption Under Singapor …
Image: https://www.abnewswire.com/upload/2025/11/e9a6696a63928d207152b4c13b42d7d5.jpg
SINGAPORE - November 18th, 2025 - CloudMile, a leading AI company in Asia, has been appointed by Digital Industry Singapore (DISG) as one of the technology partners under the Enterprise Compute Initiative (ECI). This partnership marks a significant step in Singapore's national push to strengthen AI adoption and innovation across its enterprise landscape, as outlined in Budget 2025.
CloudMile Named Key Partner in Singapore's National AI Push Under Budget 2025
Launched…
Red Oak Hospice Brings Compassionate Care to Bridgeton: Tailored Palliative and …
Red Oak Hospice brings tailored palliative and hospice care to Bridgeton, ensuring local families receive compassionate support when they need it most.
Bridgeton, NJ - Red Oak Hospice, a trusted provider of compassionate end-of-life care, is proud to offer its expert hospice care services to families in the Bridgeton, NJ area. With a focus on personalized care, Red Oak Hospice ensures that individuals facing life-limiting illnesses and their families receive the…
MyIPNow Launches as a Next-Generation Suite of Free IP & Networking Tools for Gl …
So, there's this new thing called MyIPNow that just launched. It's basically a bunch of free tools for checking your IP address and other network stuff. It seems like they're trying to make it easier for everyone, no matter where they are, to get a handle on their internet connection and security. I've been hearing a bit about it, and it sounds like it could be pretty handy.
Key Takeaways
* MyIPNow…
Pixazo Launches Unified Visual AI API to Power the Next Generation of Multimodal …
Pixazo launches a Unified Visual AI API offering one-key access to 600+ models for image, video, audio, avatar, lip sync, and virtual try-on generation.
New Delhi, India - November 18, 2025 - Pixazo [https://www.pixazo.ai/] today announced the launch of its Unified Visual AI API, a single-key platform engineered to power the next great leap in digital creativity. As the world moves beyond text-based intelligence and into a multimodal era, Pixazo aims…
More Releases for Castrate
Castrate-Sensitive Prostate Cancer Market Set to Witness Significant Growth by 2 …
Introduction
Prostate cancer remains one of the most commonly diagnosed cancers in men worldwide. Within this space, castrate-sensitive prostate cancer (CSPC) refers to prostate cancer that still responds to therapies lowering testosterone levels, typically through androgen deprivation therapy (ADT). While ADT has long been the mainstay of CSPC treatment, disease progression remains a challenge, often leading to castrate-resistant prostate cancer (CRPC).
In recent years, the treatment paradigm for CSPC has changed dramatically.…
Castrate-Resistant Prostate Cancer Market to Exceed USD 30.1 Billion by 2034
Prostate cancer is one of the most prevalent cancers among men worldwide. While androgen deprivation therapy (ADT) remains the standard first-line treatment, many patients eventually develop Castrate-Resistant Prostate Cancer (CRPC) - a stage where the disease progresses despite low testosterone levels. CRPC is an aggressive and often metastatic form of prostate cancer that demands advanced treatment strategies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71187
With the growing global prostate…
Castrate resistant Prostate Cancer Market is expected to Double Its Size by Upco …
The latest study released on the Global Castrate-resistant Prostate Cancer Market by USD Analytics evaluates market size, trends, and forecast to 2032. The Castrate-resistant Prostate Cancer market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key…
Castrate-Resistant Prostate Cancer Market: Growing Demand, Innovative Therapies …
Castrate-Resistant Prostate Cancer, or CRPC, represents an advanced stage of prostate cancer that no longer responds to traditional hormone therapy or androgen deprivation treatments, which are designed to lower testosterone levels that typically fuel prostate cancer growth. Unlike earlier-stage prostate cancers, CRPC continues to progress even when testosterone is reduced to very low levels. This stage of cancer presents new challenges and often requires more complex treatment approaches, making the…
Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical …
DelveInsight's, "Castrate Resistant Prostrate Cancer Pipeline Insight, 2024," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options…
Castrate-Resistant Prostate Cancer Market Size is Expected to Grow by 2032 | Del …
DelveInsight's "Castrate-resistant Prostate Cancer (CRPC) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Castrate-resistant Prostate Cancer (CRPC), historical and forecasted epidemiology as well as the Castrate-resistant Prostate Cancer (CRPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Takeaways from the Castrate resistant Prostate Cancer Market Research Report
• The increase in Castrate resistant Prostate Cancer Market Size is…
